1. |
Asthma Committee, Respiratory Society, Chinese Medical Associ-ation. China Guideline on the Prevention and Treatment of Asth-ma. Chin J Tubere Respir Dis, 2013, 36(5): 3331-336.
|
2. |
Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J, 2008, 31(1): 143-178.
|
3. |
Price D, Robertson A, Bullen K, et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med, 2010, 10: 1.
|
4. |
Bateman ED, Bleecker ER, Lotvall J, et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med, 2012, 106(5): 642-650.
|
5. |
Bleecker ER, Lotvall J, O'Byrne PM, et al. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. J Allergy Clin Immunol Pract, 2014, 2(5): 553-561.
|
6. |
Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax, 2012, 67(1): 35-41.
|
7. |
Woodcock A, Bleecker ER, Busse WW, et al. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res, 2011, 12: 160.
|
8. |
Woodcock A, Bateman ED, Busse WW, et al. Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. Respir Res, 2011, 12: 132.
|
9. |
Rossios C, To Y, To M, et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol, 2011, 670(1): 244-251.
|
10. |
Allen A, Bareille PJ, Rousell VM. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet, 2013, 52(1): 37-42.
|
11. |
National AE, Prevention P. Expert Panel Report 3(EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol, 2007, 120(5 Suppl): S94-138.
|
12. |
O'Byrne PM, Woodcock A, Bleecker ER, et al. Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. Respir Res, 2014, 15: 88.
|
13. |
Busse WW, Bateman ED, O'Byrne PM, et al. Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial. Allergy, 2014, 69(11): 1522-1530.
|
14. |
O'Byrne PM, Bleecker ER, Bateman ED, et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J, 2014, 43(3): 773-782.
|
15. |
Bateman ED, O'Byrne PM, Busse WW, et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax, 2014, 69(4): 312-319.
|
16. |
Bernstein DI, Bateman ED, Woodcock A, et al. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma. J Asthma, 2015, 52(10): 1073-1083.
|
17. |
Denner DR, Doeing DC, Hogarth DK, et al. Airway Inflammation after Bronchial Thermoplasty for Severe Asthma. Ann Am Thorac Soc, 2015, 12(9): 1302-1309.
|
18. |
Rodrigo GJ, Castro-Rodriguez JA. Tiotropium for the treatment of adolescents with moderate to severe symptomatic asthma: a systematic review with meta-analysis. Ann Allergy Asthma Immunol, 2015, 115(3): 211-216.
|
19. |
冯晓凯. 我国支气管哮喘患病情况及相关危险因素的流行病学调查. 北京: 北京协和医学院, 2014.
|
20. |
Finkelstein Y, Bournissen FG, Hutson JR, et al. Polymorphism of the ADRB2 gene and response to inhaled beta- agonists in children with asthma: a meta-analysis. J Asthma, 2009, 46(9): 900-905.
|
21. |
Wenzel SE, Balzar S, Ampleford E, et al. IL4R alpha mutations are associated with asthma exacerbations and mast cell/IgE expression. Am J Respir Crit Care Med, 2007, 175(6): 570-576.
|
22. |
Loza MJ, Chang BL. Association between Q551R IL4R genetic variants and atopic asthma risk demonstrated by meta-analysis. J Allergy Clin Immunol, 2007, 120(3): 578-585.
|
23. |
程江华. 支气管哮喘患者吸入糖皮质激素治疗依从性的研究. 中国实用医药, 2016, 11(11): 195-196.
|
24. |
谢先茂. 支气管哮喘患者治疗依从性与疾病控制的关联性研究. 中国当代医药, 2016, 23(26): 31-33.
|
25. |
Biggadike K, Bledsoe RK, Hassell AM, et al. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J Med Chem, 2008, 51(12): 3349-3352.
|
26. |
Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol, 2007, 293(3): L660-667.
|
27. |
Bleecker ER, Bateman ED, Busse WW, et al. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Ann Allergy Asthma Immunol, 2012, 109(5): 353-358.
|
28. |
Richter A, Anton SF, Koch P, et al. The impact of reducing dose frequency on health outcomes. Clin Ther, 2003, 25(8): 2307-2335.
|
29. |
Guest JF, Davie AM, Ruiz FJ, et al. Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim Care Respir J, 2005, 14(2): 88-98.
|